# R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty

> **NCT04120350** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 47 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Rituximab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT04120350
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-16
- **Primary completion:** 2022-08
- **Final completion:** 2024-08
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2020-06-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120350, "R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04120350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*